Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Duration of androgen suppression in the treatment of prostate cancer.

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.

N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.

2.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
3.

Maximal androgen blockade for advanced prostate cancer.

Klotz L.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004. Review.

PMID:
18471790
4.

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Wellington K, Keam SJ.

Drugs. 2006;66(6):837-50. Review. Erratum in: Drugs. 2006;66(15):1987.

PMID:
16706554
5.

Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.

Akaza H.

Cancer Sci. 2011 Jan;102(1):51-6. doi: 10.1111/j.1349-7006.2010.01774.x. Epub 2010 Nov 22. Review.

6.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
7.

[Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].

Bolla M, Fourneret P, Beneyton V, Tessier A, Jover F, Verry C.

Cancer Radiother. 2010 Oct;14(6-7):510-4. doi: 10.1016/j.canrad.2010.07.226. Epub 2010 Aug 21. Review. French.

PMID:
20728391
8.

Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review.

Sasse AD, Sasse E, Carvalho AM, Macedo LT.

BMC Cancer. 2012 Feb 2;12:54. doi: 10.1186/1471-2407-12-54. Review.

10.

Combined hormone therapy and radiation therapy for locally advanced prostate cancer.

Bolla M, Laramas M; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).

Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e30-4. doi: 10.1016/j.critrevonc.2010.11.003. Epub 2010 Dec 8. Review.

PMID:
21144766
11.

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.

Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF.

BMC Urol. 2014 Jan 25;14:9. doi: 10.1186/1471-2490-14-9. Review.

12.

[Association of radiotherapy and hormonotherapy in locally advanced prostate cancer].

Quero L, Wong-Hee-Kam S, Rivera S, Hennequin C.

Bull Cancer. 2012 Jul;99 Suppl 1:S30-6. doi: 10.1684/bdc.2012.1567. Review. French.

PMID:
22516590
13.

Intermittent androgen suppression for prostate cancer.

Buchan NC, Goldenberg SL.

Nat Rev Urol. 2010 Oct;7(10):552-60. doi: 10.1038/nrurol.2010.141. Epub 2010 Sep 14. Review.

PMID:
20842189
14.

Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?

Zumsteg ZS, Zelefsky MJ.

Lancet Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0. Review.

PMID:
22652234
15.

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.

Kunath F, Borgmann H, Blümle A, Keck B, Wullich B, Schmucker C, Sikic D, Roelle C, Schmidt S, Wahba A, Meerpohl JJ.

BMJ Open. 2015 Nov 13;5(11):e008217. doi: 10.1136/bmjopen-2015-008217. Review.

16.

Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.

Nishiyama T.

J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):179-90. doi: 10.1016/j.jsbmb.2011.12.019. Epub 2012 Jan 17. Review.

PMID:
22269996
17.

The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer.

Crook J.

Curr Opin Support Palliat Care. 2013 Sep;7(3):258-64. doi: 10.1097/SPC.0b013e328363602e. Review.

PMID:
23912384
18.

Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses.

Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N.

Clin Oncol (R Coll Radiol). 2014 Oct;26(10):e21-46. doi: 10.1016/j.clon.2014.06.016. Epub 2014 Jul 21. Review.

PMID:
25059922
19.

[Androgen deprivation and cardiovascular risk in prostate cancer treatment].

Leclercq C, Bouchot O, Azzouzi AR, Joly F, Miaadi N, Pfister C, Vincendeau S, de Crevoisier R.

Prog Urol. 2012 Sep;22 Suppl 2:S48-54. doi: 10.1016/S1166-7087(12)70036-2. Review. French.

PMID:
23098790
20.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Connolly RM, Carducci MA, Antonarakis ES.

Asian J Androl. 2012 Mar;14(2):177-86. doi: 10.1038/aja.2011.103. Epub 2012 Jan 9. Review.

Items per page

Supplemental Content

Write to the Help Desk